Table 22.
One-, Two-, Three-, Four-, Five-, and Ten-Year Relative Survival Ratesa,b for Selected Malignant Brain and Central Nervous System Tumors by Histology, SEER 18 Registries, 1995–2011c
| Histology | N | 1-Year |
2-Year |
3-Year |
4-Year |
5-Year |
10-Year |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | % | 95% CI | ||
| Pilocytic astrocytoma | 3,556 | 98.0 | (97.4–98.4) | 96.6 | (95.9–97.2) | 95.6 | (94.8–96.3) | 94.7 | (93.7–95.4) | 94.1 | (93.1–94.9) | 91.9 | (90.5–93.0) |
| Diffuse astrocytoma | 6,267 | 71.9 | (70.7–73.0) | 61.1 | (59.9–62.4) | 54.9 | (53.6–56.2) | 50.7 | (49.3–52.0) | 47.4 | (46.0–48.8) | 37.0 | (35.4–38.6) |
| Anaplastic astrocytoma | 3,780 | 61.3 | (59.7–62.9) | 43.3 | (41.6–45.0) | 35.0 | (33.4–36.7) | 30.6 | (28.9–32.2) | 27.3 | (25.6–28.9) | 19.0 | (17.3–20.7) |
| Glioblastoma | 30,611 | 36.5 | (36.0–37.1) | 14.8 | (14.3–15.2) | 8.7 | (8.3–9.0) | 6.3 | (6.0–6.6) | 5.0 | (4.8–5.4) | 2.6 | (2.3–2.9) |
| Oligodendroglioma | 3,406 | 94.0 | (93.1–94.8) | 89.6 | (88.5–90.7) | 86.0 | (84.7–87.3) | 82.7 | (81.2–84.1) | 79.5 | (77.9–81.0) | 62.8 | (60.5–65.1) |
| Anaplastic oligodendroglioma | 1,340 | 81.3 | (79.1–83.4) | 68.6 | (65.9–71.2) | 61.8 | (58.9–64.6) | 56.7 | (53.7–59.6) | 52.2 | (49.1–55.1) | 39.3 | (35.7–42.8) |
| Ependymal tumors | 2,734 | 93.7 | (92.6–94.6) | 89.7 | (88.4–90.9) | 86.8 | (85.2–88.1) | 84.7 | (83.0–86.2) | 83.3 | (81.6–84.9) | 79.2 | (76.8–81.3) |
| Oligoastrocytic tumors | 1,986 | 87.3 | (85.7–88.7) | 77.2 | (75.1–79.1) | 70.6 | (68.4–72.8) | 65.3 | (62.9–67.6) | 61.1 | (58.6–63.6) | 46.9 | (43.7–50.1) |
| Glioma malignant, NOS | 4,364 | 62.6 | (61.0–64.0) | 51.7 | (50.2–53.3) | 48.3 | (46.7–49.9) | 46.5 | (44.8–48.1) | 45.1 | (43.4–46.7) | 40.3 | (38.5–42.2) |
| Neuronal and mixed neuronal-glial tumors | 500 | 91.1 | (88.0–93.4) | 84.0 | (80.1–87.2) | 80.2 | (75.9–83.8) | 77.0 | (72.4–81.0) | 76.7 | (71.9–80.8) | 62.8 | (55.6–69.3) |
| Embryonal tumors | 2,855 | 81.6 | (80.1–83.0) | 71.7 | (69.9–73.4) | 66.8 | (64.9–68.6) | 63.7 | (61.8–65.6) | 61.2 | (59.3–63.2) | 54.2 | (51.9–56.4) |
| Medulloblastomad | 1,690 | 88.5 | (86.9–90.0) | 82.0 | (80.0–83.9) | 77.4 | (75.1–79.4) | 74.2 | (71.9–76.4) | 71.7 | (69.2–74.0) | 63.3 | (60.3–66.1) |
| Primitive neuroectodermal tumore | 679 | 75.8 | (72.4–78.9) | 60.5 | (56.6–64.2) | 54.7 | (50.7–58.5) | 51.4 | (47.3–55.2) | 49.1 | (45.1–53.0) | 42.6 | (38.3–46.7) |
| Atypical teratoid/rhabdoid tumorf | 203 | 49.6 | (42.4–56.4) | 33.8 | (26.9–40.8) | 29.4 | (22.7–36.4) | 28.5 | (21.9–35.5) | 27.4 | (20.7–34.5) | 25.9 | (19.0–33.3) |
| Other embryonal histologiesg | 283 | 76.9 | (71.4–81.5) | 64.4 | (58.2–69.9) | 59.9 | (53.5–65.7) | 56.9 | (50.3–62.8) | 53.4 | (46.7–59.6) | 50.2 | (43.1–57.0) |
| Meningioma | 1,180 | 83.2 | (80.7–85.4) | 76.0 | (73.1–78.7) | 71.4 | (68.2–74.3) | 68.9 | (65.6–72.0) | 65.4 | (61.8–68.7) | 57.2 | (52.6–61.5) |
| Lymphoma | 4,832 | 48.2 | (46.7–49.6) | 39.4 | (37.9–40.9) | 34.8 | (33.3–36.3) | 31.5 | (30.1–33.0) | 29.3 | (27.8–30.8) | 21.6 | (19.9–23.3) |
| TOTAL: All Brain and Other Nervous Systemh | 72,111 | 57.7 | (57.4–58.1) | 43.8 | (43.4–44.2) | 38.7 | (38.4–39.1) | 36.0 | (35.6–36.4) | 34.2 | (33.8–34.6) | 28.5 | (28.1–28.9) |
aThe cohort analysis of survival rates was utilized for calculating the survival estimates presented in this table. Long-term cohort-based survival estimates reflect the survival experience of individuals diagnosed over the time period, and they may not necessarily reflect the long-term survival outlook of newly diagnosed cases.
bRates are an estimate of the percentage of patients alive at one, two, three, four, five, and ten year, respectively.
cEstimated by CBTRUS using Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2013 Sub (1973–2011 varying) - Linked To County Attributes - Total U.S., 1969–2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2013 submission.
dICD-O-3 histology codes: 9470/3, 9471/3, 9472/3,9474/3.
eICD-O-3 histology code: 9473/3.
fICD-O-3 histology code: 9508/3.
gICD-O-3 histology codes: 8963/3, 9364/3, 9490/0 , 9490/3, 9500/3, 9501/3, 9502/3.
hIncludes histologies not listed in this table.
Abbreviation: SEER, Survival, Epidemiology and End Results; CI, confidence interval; NOS, not otherwise specified.